1. Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019,156(2): 477-491.
2. Kestav K, Uri A , Lavogina D.Structure, Roles and Inhibitors of a Mitotic Protein Kinase Haspin. Curr Med Chem.2017,24(21): 2276-229.
3. Amoussou NG, Bigot A,Roussakis C. Haspin: a promising target for the design of inhibitors as potent anticancer drugs. Drug Discov Today. 2018,23(2): 409-415.
4. Han L, Wang P, Sun Y, Liu S,Dai J. Anti-Melanoma Activities of Haspin Inhibitor CHR-6494 Deployed as a Single Agent or in a Synergistic Combination with MEK Inhibitor. J Cancer.2017,8(15): 2933-2943.
5. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.2018, 68(6): 394-424.
6. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma SARAH: an open-label randomised controlled phase 3 trial. Lancet Oncol.2017,18(12): 1624-1636.
7. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet.2018,391: 1163-1173.
8. Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell.2017,169(7): 1327-1341.
9. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009,373: 614-616.
10. Qiu J, Peng B, Tang Y, Qian Y, Guo P, Li M, et al. CpG Methylation Signature Predicts Recurrence in Early-Stage Hepatocellular Carcinoma: Results From a Multicenter Study. J Clin Oncol.2017,35(7): 734-742.
11. Li X, Yao W, Yuan Y, Chen P, Li B, Li J, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signaling as a therapeutic strategy against hepatocellular carcinoma. Gut.2017,66(1): 157-167.
12. Greten TF, Lai CW, Li G, Staveley-O'Carroll KF. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. Gastroenterology.2019,156(2): 510-524.
13. Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, et al. Palbociclib PD-0332991, a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut.2017,66(7): 1286-1296.
14. Dawkins J,Webster RM. The hepatocellular carcinoma market. Nat Rev Drug Discov.2019,18(1): 13-14.
15. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet.2018,391: 1301-1314.
16. Dai J, Sullivan BA, Higgins JM. Regulation of mitotic chromosome cohesion by Haspin and Aurora B. Dev Cell.2006,11(5): 741-750.
17. Berthier A, Jiménez-Sáinz J, Pulido R. PINK1 regulates histone H3 trimethylation and gene expression by interaction with the polycomb protein EED/WAIT1. Proc Natl Acad Sci U S A.2013,110(36):14729-14734.
18. Khan SA, Amnekar R, Khade B, Barreto SG, Ramadwar M, Shrikhande SV, Gupta S. p38-MAPK/MSK1-mediated overexpression of histone H3 serine 10 phosphorylation defines distance-dependent prognostic value of negative resection margin in gastric cancer. Clin Epigenetics.2016,8:88.
19. Kurihara D, Matsunaga S, Omura T, Higashiyama T, Fukui K. Identification and characterization of plant Haspin kinase as a histone H3 threonine kinase. BMC Plant Biol.2011,11:73.
20. Maiolica A, de Medina-Redondo M, Schoof EM, Chaikuad A, Villa F, Gatti M, et al. Modulation of the chromatin phosphoproteome by the Haspin protein kinase. Mol Cell Proteomics.2014,13(7): 1724-1740.
21. Wang F, Ulyanova NP, Daum JR, Patnaik D, Kateneva AV, Gorbsky GJ, Higgins JM. Haspin inhibitors reveal centromeric functions of Aurora B in chromosome segregation. J Cell Biol.2012,199(2):251-68.
22. Lavogina D, Kestav K, Chaikuad A, Heroven C, Knapp S, Uri A. Co-crystal structures of the protein kinase haspin with bisubstrate inhibitors. Acta Crystallogr F Struct Biol Commun.2016,72: 339-345.
23. Higgins JM. The Haspin gene: location in an intron of the integrin alphaE gene, associated transcription of an integrin alphaE-derived RNA and expression in diploid as well as haploid cells. Gene.2001,267: 55-69.
24. Dai J, Sultan S, Taylor SS, Higgins JM. The kinase haspin is required for mitotic histone H3 Thr3 phosphorylation and normal metaphase chromosome alignment. Genes Dev.2005,19: 472-488.
25. Cuny GD, ΜL yanova NP, Patnaik D, Liu JF, Lin X, Auerbach K, et al. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors. Bioorg Med Chem Lett.2012, 22(5): 2015-2019.
26. Han L, Wang P, Sun Y, Liu S, Dai J. Anti-Melanoma Activities of Haspin Inhibitor CHR-6494 Deployed as a Single Agent or in a Synergistic Combination with MEK Inhibitor. J Cancer.2017, 8(15): 2933-2943.
27. Jong-Eun Kim, Sung-Young Lee, Mi Jang. Coumestrol Epigenetically Suppresses Cancer Cell Proliferation: Coumestrol Is a Natural Haspin Kinase Inhibitor. Int J Mol Sci.2017,18(10): 2228.
28. Kestav K, Lavogina D, Raidaru G, Chaikuad A, Knapp S, Uri A. Bisubstrate inhibitor approach for targeting mitotic kinase Haspin. Bioconjug Chem.2015, 26(2): 225-34.
29. Magne L, Blanc E, Marchand A, Fafournoux P, Barouki R, Rouach H,Garlatti M. Stabilization of IGFBP-1 mRNA by ethanol in hepatoma cells involves the JNK pathway. J Hepatol.2007,47(5):691-698.
30. Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer.2014,14(5):329-341.
31. Chunhui Nie, Bei Wang, Baoquan Wang, Ning Lv, Rui Yu, Enfan Zhang. Protopine triggers apoptosis via the intrinsic pathway and regulation of ROS/PI3K/Akt signalling pathway in liver carcinoma. Cancer Cell International. 2021, 21(1):396.
32. Le Fuyin,Yang Lilan,Han Yiwen, Zhong Yanying, Zhan Fuliang, Feng Ying, et al. TPL Inhibits the Invasion and Migration of Drug-Resistant Ovarian Cancer by Targeting the PI3K/AKT/NF-κB-Signaling Pathway to Inhibit the Polarization of M2 TAMs.Front Oncol.2021, 11: 704001.
33. Haiqun Chen, Gang Dai, Yiting Cai, Qinhao Gong, Wei Wu, Min Gao, et al. Vasodilator-stimulated phosphoprotein (VASP), a novel target of miR-4455, promotes gastric cancer cell proliferation, migration, and invasion, through activating the PI3K/AKT signaling pathway. Cancer Cell International,2018,18:97.